XTL Biopharmaceuticals Ltd.
Index- P/E- EPS (ttm)-0.50 Insider Own18.81% Shs Outstand5.41M Perf Week-6.06%
Market Cap10.07M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.61M Perf Month-21.19%
Income- PEG- EPS next Q- Inst Own9.23% Short Float0.22% Perf Quarter-24.70%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.16 Perf Half Y-51.94%
Book/sh0.60 P/B3.10 EPS next Y- ROA- Target Price- Perf Year-44.48%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.48 - 6.69 Perf YTD-32.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-72.20% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low25.68% ATR0.16
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)40.26 Volatility10.41% 6.17%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.41 Prev Close1.64
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume6.75K Price1.86
Recom- SMA20-10.96% SMA50-15.14% SMA200-40.58% Volume9,530 Change13.41%
May-08-15Initiated H.C. Wainwright Buy $6
Nov-21-18 08:00AM  
Nov-01-18 10:09AM  
Jul-24-18 09:09AM  
May-29-18 05:37PM  
Dec-13-17 07:30AM  
Dec-06-17 12:08PM  
Nov-27-17 10:30AM  
Oct-23-17 11:23AM  
Oct-06-17 07:30AM  
Oct-05-17 07:50AM  
Sep-26-17 09:23AM  
Sep-12-17 09:00AM  
Jul-11-17 07:00AM  
Jun-15-17 09:00AM  
Apr-27-17 09:50AM  
Apr-05-17 09:10AM  
Mar-30-17 08:55AM  
Mar-22-17 09:22AM  
Mar-07-17 12:40PM  
Mar-01-17 08:30AM  
Feb-17-17 08:00AM  
Feb-13-17 09:08AM  
Jan-25-17 08:30AM  
Jan-05-17 08:30AM  
Dec-19-16 08:00AM  
Dec-06-16 08:30AM  
Nov-09-16 01:25PM  
Sep-27-16 08:30AM  
Sep-07-16 08:32AM  
Sep-06-16 08:00AM  
Aug-11-16 09:00AM  
Jun-02-16 09:11AM  
Jun-01-16 08:30AM  
May-16-16 11:45AM  
Apr-07-16 01:04PM  
Mar-31-16 09:45AM  
Mar-21-16 08:30AM  
Mar-09-16 08:29AM  
Mar-02-16 09:00AM  
Feb-22-16 09:02AM  
Feb-10-16 08:30AM  
Jan-27-16 08:30AM  
Jan-25-16 08:30AM  
Jan-13-16 08:30AM  
Jan-11-16 08:30AM  
Dec-01-15 08:30AM  
Nov-09-15 08:30AM  
Oct-28-15 09:00AM  
Oct-26-15 09:15AM  
Oct-13-15 08:45AM  
Sep-17-15 11:40AM  
Sep-03-15 09:00AM  
Sep-01-15 09:00AM  
Aug-26-15 09:00AM  
Jun-01-15 08:00AM  
May-11-15 10:50AM  
May-09-15 09:45AM  
May-08-15 09:35AM  
Apr-28-15 07:45AM  
Mar-31-15 09:30AM  
Feb-17-15 08:30AM  
Dec-30-14 12:23PM  
Dec-08-14 08:30AM  
Dec-01-14 08:00AM  
Sep-02-14 12:09PM  
Jul-22-14 02:54PM  
Jul-16-14 09:18AM  
Jun-12-14 08:00AM  
Jun-02-14 09:00AM  
May-19-14 08:00AM  
Apr-02-14 04:41PM  
Mar-25-14 08:00AM  
Jan-08-14 08:00AM  
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.